DOYLESTOWN, Pa.--(BUSINESS WIRE)--FlowMetric, Inc. a market leader in flow cytometry and cell sorting services, announced today that they have appointed Floyd E. Fox, Ph.D. as Chief Scientific Officer. Dr. Fox will be responsible for leading FlowMetric's research and development strategy and assuring all client support activities are carried out according to state of the art scientific and regulatory standards. Dr. Fox, an Immunologist by training, is an expert in the conception, development and implementation of innovative non-clinical and clinical bioanalytical methods aimed at understanding the mechanism of action of biotherapeutics. Dr. Fox has nearly 25 years' experience in the areas of non-clinical and clinical pharmacology, immunogenicity, cytokine biology, infection and inflammation, oncology and immunology.
"I anticipate that Dr. Fox's extensive experience and proficiency in formulating and executing strategic, bioanalytically focused, drug development plans, at both pre-clinical and clinical stages, together with his understanding of the worldwide health authority regulatory environment will afford FlowMetric, and particularly our clients, with exceptional added value."
Prior to joining FlowMetric, Dr. Fox served for nearly 15 years at Eli Lilly and Company (Imclone Systems) in roles of increasing responsibility as Director and Senior Director, culminating and Associate Vice-President, Clinical Pharmacology and Drug Disposition. Dr. Fox was instrumental in the US and global marketing approval of Erbitux™and Cyramza™. Prior to this role, Dr. Fox worked at Johnson and Johnson as a Senior Research Scientist in the Inflammation and Clinical Pharmacology group where he conducted research on immunogenicity of monoclonal antibody based therapeutics and contributed to the marketing approval of Remicade™.
"It is with great excitement that we welcome Floyd to FlowMetric as our Chief Scientific Officer," said Renold Capocasale, FlowMetric CEO and Founder. "I anticipate that Dr. Fox's extensive experience and proficiency in formulating and executing strategic, bioanalytically focused, drug development plans, at both pre-clinical and clinical stages, together with his understanding of the worldwide health authority regulatory environment will afford FlowMetric, and particularly our clients, with exceptional added value."
Dr. Fox has authored more than 35 peer reviewed scientific articles including several book chapters and is the holder of one US patent. He holds a Doctorate (Ph.D.) in Immunology from the University of Texas, a Master's degree (MS) in Molecular Biology and Biochemistry from New York University and a Bachelor's degree (BS) in Biology from the State University of New York at Stonybrook.
FlowMetric, Inc., is a niche contract research organization (CRO), focused on providing polychromatic flow cytometry and cell sorting services to bio-pharma and drug discovery companies. FlowMetric is committed to providing independent, unbiased, comprehensive and precise test services as part of the pre-clinical and clinical trial process for its clients. FlowMetric offers integrated, cost-effective, and specialized polychromatic flow cytometry services delivered with an uncompromising commitment to quality.
Rachel Bunting, MS, MBA